Karina Portillo1, Nancy Perez-Rodas2, Ignasi García-Olivé3, Ignasi Guasch-Arriaga2, Carmen Centeno2, Pere Serra2, Caroline Becker-Lejuez2, José Sanz-Santos2, Felip Andreo García4, Juan Ruiz-Manzano4. 1. Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Barcelona Research Network (BRN), Barcelona, España. Electronic address: karisoe@yahoo.es. 2. Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. 3. Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Barcelona, España. 4. Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Barcelona Research Network (BRN), Barcelona, España; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Barcelona, España; Departament de Medicina, Universitat Autónoma de Barcelona, Barcelona, España.
Abstract
INTRODUCTION: Information on the association of lung cancer (LC) and combined pulmonary fibrosis and emphysema (CPFE) is limited and derived almost exclusively from series in Asian populations. The main objective of the study was to assess the impact of LC on survival in CPFE patients and in patients with idiopathic pulmonary fibrosis (IPF). METHODS: A retrospective study was performed with data from patients with CFPE and IPF diagnosed in our hospital over a period of 5 years. RESULTS: Sixty-six patients were included, 29 with CPFE and 37 with IPF. Nine had a diagnosis of LC (6 with CPFE and 3 with IPF). Six patients (67%) received palliative treatment even though 3 of them were diagnosed atstage i-ii. Overall mortality did not differ significantly between groups; however, in patients with LC, survival was significantly lower compared to those without LC (P=.044). The most frequent cause of death was respiratory failure secondary to pulmonary fibrosis exacerbation (44%). In a multivariate analysis, the odds ratio of death among patients with LC compared to patients without LC was 6.20 (P=.037, 95% confidence interval: 1.11 to 34.48). CONCLUSIONS: Lung cancer reduces survival in both entities. The diagnostic and therapeutic management of LC is hampered by the increased risk of complications after any treatment modality, even after palliative treatment.
INTRODUCTION: Information on the association of lung cancer (LC) and combined pulmonary fibrosis and emphysema (CPFE) is limited and derived almost exclusively from series in Asian populations. The main objective of the study was to assess the impact of LC on survival in CPFEpatients and in patients with idiopathic pulmonary fibrosis (IPF). METHODS: A retrospective study was performed with data from patients with CFPE and IPF diagnosed in our hospital over a period of 5 years. RESULTS: Sixty-six patients were included, 29 with CPFE and 37 with IPF. Nine had a diagnosis of LC (6 with CPFE and 3 with IPF). Six patients (67%) received palliative treatment even though 3 of them were diagnosed atstage i-ii. Overall mortality did not differ significantly between groups; however, in patients with LC, survival was significantly lower compared to those without LC (P=.044). The most frequent cause of death was respiratory failure secondary to pulmonary fibrosis exacerbation (44%). In a multivariate analysis, the odds ratio of death among patients with LC compared to patients without LC was 6.20 (P=.037, 95% confidence interval: 1.11 to 34.48). CONCLUSIONS:Lung cancer reduces survival in both entities. The diagnostic and therapeutic management of LC is hampered by the increased risk of complications after any treatment modality, even after palliative treatment.
Keywords:
Combinación de fibrosis pulmonar y enfisema; Combined pulmonary fibrosis and emphysema; Cáncer de pulmón; Fibrosis pulmonar idiopática; Idiopathic pulmonary fibrosis; Lung cancer